The estimated Net Worth of Robert B Hance is at least $6.28 Million dollars as of 24 November 2020. Robert Hance owns over 10,000 units of Maravai Lifesciences stock worth over $192,516 and over the last 18 years Robert sold MRVI stock worth over $6,087,411.
Robert has made over 18 trades of the Maravai Lifesciences stock since 2007, according to the Form 4 filled with the SEC. Most recently Robert bought 10,000 units of MRVI stock worth $270,000 on 24 November 2020.
The largest trade Robert's ever made was exercising 179,997 units of Maravai Lifesciences stock on 29 February 2012 worth over $8,504,858. On average, Robert trades about 14,175 units every 112 days since 2006. As of 24 November 2020 Robert still owns at least 21,852 units of Maravai Lifesciences stock.
You can see the complete history of Robert Hance stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Maravai Lifesciences have traded over $97,620,365 worth of Maravai Lifesciences stock and bought 174,388 units worth $4,706,376 . The most active insiders traders include Investment Xi Llcmaravai Li..., Gregory T Lucier und Robert B Hance. On average, Maravai Lifesciences executives and independent directors trade stock every 142 days with the average trade being worth of $9,901,814. The most recent stock trade was executed by Investment Xi Llcmaravai Li... on 28 May 2024, trading 9,940,974 units of MRVI stock currently worth $97,620,365.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Maravai Lifesciences executives and other stock owners filed with the SEC include: